- Home
- HOND vs DCTH Comparison
HOND vs DCTH Comparison
Compare HOND & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOND
- DCTH
- Stock Information
- Founded
- HOND 2024
- DCTH 1988
- Country
- HOND United States
- DCTH United States
- Employees
- HOND N/A
- DCTH 76
- Industry
- HOND
- DCTH Medical/Dental Instruments
- Sector
- HOND
- DCTH Health Care
- Exchange
- HOND NYSE
- DCTH Nasdaq
- Market Cap
- HOND 334.9M
- DCTH 426.3M
- IPO Year
- HOND 2024
- DCTH N/A
- Fundamental
- Price
- HOND $10.89
- DCTH $11.52
- Analyst Decision
- HOND
- DCTH Strong Buy
- Analyst Count
- HOND 0
- DCTH 4
- Target Price
- HOND N/A
- DCTH $24.00
- AVG Volume (30 Days)
- HOND 361.1K
- DCTH 873.0K
- Earning Date
- HOND 01-01-0001
- DCTH 08-04-2025
- Dividend Yield
- HOND N/A
- DCTH N/A
- EPS Growth
- HOND N/A
- DCTH N/A
- EPS
- HOND 0.20
- DCTH N/A
- Revenue
- HOND N/A
- DCTH $53,850,000.00
- Revenue This Year
- HOND N/A
- DCTH $155.42
- Revenue Next Year
- HOND N/A
- DCTH $37.93
- P/E Ratio
- HOND $53.55
- DCTH N/A
- Revenue Growth
- HOND N/A
- DCTH 1068.87
- 52 Week Low
- HOND $9.90
- DCTH $7.17
- 52 Week High
- HOND $12.24
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- HOND N/A
- DCTH 32.83
- Support Level
- HOND N/A
- DCTH $12.11
- Resistance Level
- HOND N/A
- DCTH $14.15
- Average True Range (ATR)
- HOND 0.00
- DCTH 0.57
- MACD
- HOND 0.00
- DCTH -0.16
- Stochastic Oscillator
- HOND 0.00
- DCTH 9.67
About HOND HCM II ACQUISITION CORP
HCM II Acquisition Corp is a blank check company.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.